Gene therapy
News
September 15, 2023
Genethon assesses a therapeutic potential of a Dual AAV vector approach for Duchenne muscular dystrophy
(read more)
September 11, 2023
Genethon’s Optidys project rewarded by BpiFrance as part of France 2030
(read more)
August 17, 2023
First results of Crigler-Najjar clinical trial published in New England Journal of Medicine
(read more)
July 12, 2023
Genethon and Thales collaborate on artificial intelligence to improve bioproduction efficiency
(read more)
May 30, 2023
Research work carried out at Genethon rewarded at the 26th edition of the ASGCT
(read more)
May 12, 2023
Genethon’s R&D to be Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 16-20, 2023, in Los Angeles, CA
(read more)
May 12, 2023
ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis (ALS)
(read more)
April 27, 2023
Crigler-Najjar syndrome: Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy for patients with anti-AAV antibodies
(read more)
March 6, 2023
Crigler-Najjar Syndrome: Genethon obtains PRIME priority drug status from the EMA for its gene therapy
(read more)
February 24, 2023
Chronic septic granulomatosis: biomarkers predict the efficacy of gene therapy
(read more)
February 7, 2023
"We made important achievements in 2022 but we still face key challenges in the year ahead"
(read more)
January 10, 2023
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
(read more)
December 14, 2022
Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy
(read more)
November 21, 2022
Téléthon 2022: Benjamin, a hope for families thanks to clinical trials
(read more)
November 21, 2022
Téléthon 2022 : Benjamin, l’espoir des familles grâce aux essais cliniques
(read more)
November 21, 2022
Telethon 2022: for Lucie, "a real opportunity, thanks to advances in research"
(read more)
Serving the public interest
Our mission: Conception, clinic and preclinic development of drugs of genic therapy for rare diseases
Our goal: Providing these innovative treatments to the sick
